Ciancio et al. 20106464 Ciancio G, Gaynor JJ, Roth D, Kupin W, Hanson L, Tueros L, et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Transplant Proc 2010;42:3503-6. PMID: 21094804 DOI:http://dx.doi.org/10.1016/j.transproceed.2010.08.045 http://dx.doi.org/10.1016/j.transproceed...
|
13 |
Imunoglobulina antitimócito |
0 (0%) |
0 (0%) |
0 (0%) |
13 |
Alemtuzumabe |
6 (46,2%) |
0 (0%) |
1 (7,69%) |
12 |
Daclizumabe |
0 (0%) |
0 (0%) |
0 (0%) |
|
|
(p = 0,0002) |
|
|
Brennan et al. 19992121 Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67:1011-8. PMID: 10221486 DOI:http://dx.doi.org/10.1097/00007890-199904150-00013 http://dx.doi.org/10.1097/00007890-19990...
|
48 |
Imunoglobulina antitimócito |
27 (56%) |
6 (12,5%) |
0 (0%) |
24 |
Atgam |
1 (4%) |
8 (33%) |
1 (4%) |
|
|
p = NS |
p = 0,056 |
|
Brennan et al. 20061313 Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-77. DOI: http://dx.doi.org/10.1056/NEJMoa060068 http://dx.doi.org/10.1056/NEJMoa060068...
|
141 |
Imunoglobulina antitimócito |
47 (33,3%) |
11 (7,8%) |
5 (3,5%) |
137 |
Basiliximabe |
20 (14,6%) |
24 (17,5%) |
1 (0,7%) |
|
|
p < 0,001 |
p = 0,02 |
p = 0,21 |
Noel et al. 200988 Noël C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009;20:1385-92. DOI: http://dx.doi.org/10.1681/ASN.2008101037 http://dx.doi.org/10.1681/ASN.2008101037...
|
113 |
Imunoglobulina antitimócito |
9 (7,96%) |
21 (18,6%) |
1 (0,9%) |
114 |
Daclizumabe |
5 (4,38%) |
12 (10,5%) |
0 (0%) |
|
|
p = 0,36 |
p = 0,093 |
p = NS |
Mourad et al. 20042323 Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004;78:584-90. PMID: 15446319 DOI:http://dx.doi.org/10.1097/01.TP.0000129812.68794.CC http://dx.doi.org/10.1097/01.TP.00001298...
|
53 |
Imunoglobulina antitimócito |
27 (51%) |
22 (41,5%) |
NR |
52 |
Basiliximabe |
10 (19,2%) |
11 (21,2%) |
|
|
|
p = 0,0007 |
p = 0,025 |
|
Abou-Ayache et al. 20082626 Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, et al. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. Nephrol Dial Transplant 2008;23:2024-32. DOI: http://dx.doi.org/10.1093/ndt/gfm873 http://dx.doi.org/10.1093/ndt/gfm873...
|
55 |
Imunoglobulina antitimócito |
NR |
19 (68%) |
0 (0%) |
54 |
Daclizumabe |
|
18 (83%) |
0 (0%) |
Ciancio et al. 2005/20082727 Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005;80:457-65. PMID: 16123718 DOI: http://dx.doi.org/10.1097/01.tp.0000165847.05787.08 http://dx.doi.org/10.1097/01.tp.00001658...
,6565 Ciancio G, Burke GW, Gaynor JJ, Roth D, Kupin W, Rosen A, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008;22:200-10. DOI:http://dx.doi.org/10.1111/j.1399-0012.2007.00774.x http://dx.doi.org/10.1111/j.1399-0012.20...
|
30 |
Imunoglobulina antitimócito |
NR |
1 (3,33%) |
0 (0%) |
30 |
Alemtuzumabe |
|
2 (6,66%) |
0 (0%) |
30 |
Daclizumabe |
|
0 (0%) |
1 (3,33%) |
Khosroshahi et al. 20081111 Khosroshahi HT, Tubbs RS, Shoja MM, Ghafari A, Noshad H, Ardalan MR. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection. Transplant Proc 2008;40:137-9. PMID: 18261569 DOI: http://dx.doi.org/10.1016/j.transproceed.2007.12.016 http://dx.doi.org/10.1016/j.transproceed...
|
37 |
Imunossupressão
|
NS |
NR |
NR |
31 |
Imunossupressão + Imunoglobulina antitimócito |
|
|
|
Farney et al. 200855 Farney A, Sundberg A, Moore P, Hartmann E, Rogers J, Doares W, et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008;22:41-9.
|
45 |
Imunoglobulina antitimócito |
NR |
2 (4,44%) |
NR |
32 |
Alemtuzumabe |
|
1 (3,12%) |
|
|
|
|
p = NS |
|
Hernandez et al. 20071818 Hernández D, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007;84:706-14. PMID: 17893603 DOI:http://dx.doi.org/10.1097/01.tp.0000282872.17024.b7 http://dx.doi.org/10.1097/01.tp.00002828...
|
80 |
Imunoglobulina antitimócito + Ciclosporina + Azatioprina |
NR |
33 (41%) |
3 (3,75%) |
80 |
Basiliximabe + Ciclosporina + MMF |
|
16 (20%) |
2 (2,5%) |
80 |
Basiliximabe + Tacrolimus + MMF |
|
20 (25%) |
2 (2,5%) |
|
|
|
p = 0,008 |
|
Thomas et al. 20071616 Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007;83:1509-12. PMID: 17565326 DOI:http://dx.doi.org/10.1097/01.tp.0000263344.53000.a1 http://dx.doi.org/10.1097/01.tp.00002633...
|
11 |
Alemtuzumabe + Tacrolimus |
p < 0,05 a favor do Alemtuzumabe |
NR |
0 (0%) |
10 |
Imunoglobulina antitimócito + Tacrolimus + MMF + corticoide |
|
|
0 (0%) |
Goggins et al. 200366 Goggins WC, Pascual MA, Powelson JA, Magee C, Tolkoff-Rubin N, Farrell ML, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003;76:798-802. PMID: 14501856 DOI:http://dx.doi.org/10.1097/01.TP.0000081042.67285.91 http://dx.doi.org/10.1097/01.TP.00000810...
|
27 |
Imunoglobulina antitimócito IO |
NR |
1 (3,7%) |
NR |
31 |
Imunoglobulina antitimócito PO |
|
2 (6,5%) |
|
|
|
|
p = NS |
|
Lebranchu et al. 200277 Lebranchu Y, Bridoux F, Büchler M, Le Meur Y, Etienne I, Toupance O, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002;2:48-56. DOI: http://dx.doi.org/10.1034/j.1600-6143.2002.020109.x http://dx.doi.org/10.1034/j.1600-6143.20...
|
50 |
Basiliximabe + ciclosporina |
0 (0%) |
6 (12%) |
0 (0%) |
50 |
Imunoglobulina antitimócito + ciclosporina |
5 (10%) |
19 (38%) |
0 (0%) |
|
|
p < 0,03 |
p = 0,005 |
|
Charpentier et al. 20031414 Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003;75:844-51. DOI: http://dx.doi.org/10.1097/01.TP.0000056635.59888.EF http://dx.doi.org/10.1097/01.TP.00000566...
|
185 |
Tacrolimus |
16 (8,6%) |
29 (15,7%) |
1 (0,54%) |
186 |
Imunoglobulina antitimócito + |
72 (38,7%) |
45 (24,2%) |
2 (1,07%) |
184 |
Tacrolimus |
64 (34,8%) |
52 (28,3%) |
4 (2,17%) |
|
Imunoglobulina antitimócito + ciclosporina |
p < 0,001 |
p = 0,012 |
|
Thibaudin et al. 19981515 Thibaudin D, Alamartine E, de Filippis JP, Diab N, Laurent B, Berthoux F. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998;13:711-5. PMID:9550651
|
42 |
Imunossupressão
|
7 (17%) |
17 (40%) |
NR |
47 |
Imunossupressão + Imunoglobulina antitimócito |
20 (43%) |
28 (59%) |
|
|
|
p = 0,007 |
p = NS |
|
Kyllonen et al. 20071212 Kyllonen LE, Eklund BH, Pesonen EJ, Salmela KT. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation 2007;84:75-82. PMID: 17627241 DOI:http://dx.doi.org/10.1097/01.tp.0000268084.64888.f3 http://dx.doi.org/10.1097/01.tp.00002680...
|
53 |
Imunoglobulina antitimócito vs. Basiliximabe vs. Imunossupressão
|
NR |
9 (17%) |
2 (3,77%) |
58 |
|
|
9 (16%) |
0 (0%) |
44 |
|
|
5 (11%) |
1 (2,27%) |
|
|
|
p = NS |
p = NS |
Soulillou et al. 199099 Soulillou JP, Cantarovich D, Le Mauff B, Giral M, Robillard N, Hourmant M, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990;322:1175-82. PMID: 2157982 DOI: http://dx.doi.org/10.1056/NEJM199004263221702 http://dx.doi.org/10.1056/NEJM1990042632...
|
50 |
Imunoglobulina antitimócito vs. 33B3.1 |
> no braço de Imunoglobulina antitimócito |
9 (18%) |
NR |
50 |
|
p < 0,005 |
10 (20%) |
|
Theodorakis et al. 19983232 Theodorakis J, Schneeberger H, Illner WD, Stangl M, Zanker B, Land W. Aggressive treatment of the first acute rejection episode using first-line anti-lymphocytic preparation reduces further acute rejection episodes after human kidney transplantation. Transpl Int 1998;11:S86-9. DOI:http://dx.doi.org/10.1111/j.1432-2277.1998.tb01203.x http://dx.doi.org/10.1111/j.1432-2277.19...
|
25 25 |
Imunoglobulina antitimócito vs. metilprednisolone |
NR |
NS |
NR |
Baldi et al. 20002222 Baldi A, Malaise J, Mourad M, Squifflet JP. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results. Transplant Proc 2000;32:429-31. PMID: 10715467 DOI: http://dx.doi.org/10.1016/S0041-1345(00)00838-1 http://dx.doi.org/10.1016/S0041-1345(00)...
|
28 |
Imunoglobulina antitimócito vs. OKT3 |
4 (14,2%) |
2 (7,1%) |
2 (7,14%) |
28 |
|
3 (10,7%) |
3 (10,7%) |
0 (0%) |
|
|
p = NS |
p = NS |
|
Mariat et al. 19983737 Mariat C, Alamartine E, Diab N, de Filippis JP, Laurent B, Berthoux F. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transpl Int 1998;11:231-6.
|
31 |
Imunoglobulina antitimócito vs. OKT3 |
NR |
12 (39%) |
0 (0%) |
29 |
|
|
13 (45%) |
2 (7%) |
Midtvedt et al. 20033838 Midtvedt K, Fauchald P, Lien B, Hartmann A, Albrechtsen D, Bjerkely BL, et al. Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection. Clin Transplant 2003;17:69-74. DOI: http://dx.doi.org/10.1034/j.1399-0012.2003.02105.x http://dx.doi.org/10.1034/j.1399-0012.20...
|
27 |
Imunoglobulina antitimócito vs. OKT3 |
NR |
14 (51,8%) |
NR |
28 |
|
|
11 (39,2%) |
|
|
|
|
p = NS |
|
Hoitsma et al. 19823131 Hoitsma AJ, Reekers P, Kreeftenberg JG, van Lier HJ, Capel PJ, Koene RA. Treatment of acute rejection of cadaveric renal allografts with rabbit antithymocyte globulin. Transplantation 1982;33:12-6. PMID: 7039017 DOI: http://dx.doi.org/10.1097/00007890-198201000-00003 http://dx.doi.org/10.1097/00007890-19820...
|
20 |
Imunoglobulina antitimócito vs. esteroides |
NR |
NS |
NR |
20 |
|
|
|
|
Tullius et al. 20036666 Tullius SG, Pratschke J, Strobelt V, Kahl A, Reinke P, May G, et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transplant Proc 2003;35:2100-1. DOI: http://dx.doi.org/10.1016/S0041-1345(03)00679-1 http://dx.doi.org/10.1016/S0041-1345(03)...
|
62 |
Imunoglobulina antitimócito vs. Basiliximabe |
NR |
7 (11,3%) |
NR |
62 |
|
|
2 (3,22%) |
|
|
|
|
p = NS |
|